Gladius Capital Management LP Nuvation Bio Inc. Transaction History

Gladius Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	BUY	$0.96 - $1.53 $14,289 - $22,774	14,885 Added 92.56%	30,967 $46,000
Q3 2023 Dec 18, 2023	BUY	$1.26 - $2.1 $4,029 - $6,715	3,198 Added 24.82%	16,082 $21,000
Q3 2023 Oct 10, 2023	BUY	$1.26 - $2.1 $4,029 - $6,715	3,198 Added 24.82%	16,082 $22,000
Q2 2023 Dec 18, 2023	SELL	$1.56 - $1.84 $4,988 - $5,884	-3,198 Reduced 19.89%	12,884 $23,000
Q2 2023 Aug 08, 2023	SELL	$1.56 - $1.84 $2,212 - $2,609	-1,418 Reduced 9.91%	12,884 $24,000
Q1 2023 Dec 18, 2023	SELL	$1.6 - $2.48 $2,848 - $4,414	-1,780 Reduced 11.07%	14,302 $23,000
Q1 2023 May 09, 2023	SELL	$1.6 - $2.48 $8,283 - $12,838	-5,177 Reduced 26.58%	14,302 $24,000
Q4 2022 Dec 18, 2023	BUY	$1.68 - $2.5 $5,706 - $8,492	3,397 Added 21.12%	19,479 $37,000
Q4 2022 Feb 02, 2023	BUY	$1.68 - $2.5 $10,511 - $15,642	6,257 Added 47.32%	19,479 $38,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $3,834 - $53,416	13,222 New	13,222 $30,000

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.